Datamonitor launches Cardiovascular Review 

The Cardiovascular Review brings you the latest news, analysis and research in the cardiovascular industry. It covers all the major current business issues and events, including R&D, licensing deals, alliances and joint ventures, and regulatory decisions.

Scope

• Strategic insight into the future shape of cardiovascular companies and markets

• The most significant cardiovascular industry news compiled into one monthly update

• Expert analysis into the implications of the month's important cardiovascular industry events

• Insight into the future shape of the market for players at all levels

• All the month's major cardiovascular stories in headline and summary form

Report Highlights

Out of the dozens of topics covered in this month's review, the most important include:

* Pfizer's takeover of Pharmacia could be the first step in a wave of pharma industry consolidation. Rivals such as GlaxoSmithKline, Aventis, AstraZeneca, Merck and Bristol-Myers Squibb may have to follow suit, or risk being overwhelmed.

* Significant treatments are being developed in the field of cardiovascular research, with Merck's Zocor leading the way - it's recently been found to have a significant effect in reducing the risk of heart attack and stroke.

Reasons to Purchase

• Not only keeps you updated about industry events - it also gives you opinion and insight

• The most significant cardiovascular industry news compiled into one monthly update

• Draws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest events

• Insight into the future shape of the market for players at all levels

• All the month's cardiovascular stories in headline and summary form

View pdf brochure

Click here to purchase online